title: Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF.
abstract: To fully assess the role of VEGF-A in tumor angiogenesis, antibodies that can block all sources of vascular endothelial growth factor (VEGF) are desired. Selectively targeting tumor-derived VEGF overlooks the contribution of host stromal VEGF. Other strategies, such as targeting VEGF receptors directly or using receptor decoys, result in inhibiting not only VEGF-A but also VEGF homologues (e.g. placental growth factor, VEGF-B, and VEGF-C), which may play a role in angiogenesis. Here we report the identification of novel anti-VEGF antibodies, B20 and G6, from synthetic antibody phage libraries, which block both human and murine VEGF action in vitro. Their affinity-improved variants completely inhibit three human tumor xenografts in mice of skeletal muscle, colorectal, and pancreatic origins (A673, HM-7, and HPAC). Avastin, which only inhibits the tumor-derived human VEGF, is approximately 90% effective at inhibiting HM-7 and A673 growth but is <50% effective at inhibiting HPAC growth. Indeed, HPAC tumors contain more host stroma invasion and stroma-derived VEGF than other tumors. Thus, the functional contribution of stromal VEGF varies greatly among tumors, and systemic blockade of both tumor and stroma-derived VEGF is sufficient for inhibiting the growth of tumor xenografts.
authors.affiliation: Department of Protein Engineering, Genentech Inc., South San Francisco, CA 94080, USA.
authors.forename: Wei-Ching
authors.initials: WC
authors.lastname: Liang
authors.forename: Xiumin
authors.initials: X
authors.lastname: Wu
authors.forename: Franklin V
authors.initials: FV
authors.lastname: Peale
authors.forename: Chingwei V
authors.initials: CV
authors.lastname: Lee
authors.forename: Y Gloria
authors.initials: YG
authors.lastname: Meng
authors.forename: Johnny
authors.initials: J
authors.lastname: Gutierrez
authors.forename: Ling
authors.initials: L
authors.lastname: Fu
authors.forename: Ajay K
authors.initials: AK
authors.lastname: Malik
authors.forename: Hans-Peter
authors.initials: HP
authors.lastname: Gerber
authors.forename: Napoleone
authors.initials: N
authors.lastname: Ferrara
authors.forename: Germaine
authors.initials: G
authors.lastname: Fuh
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D045744:Cell Line, Tumor; D002478:Cells, Cultured; D004195:Disease Models, Animal; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000166:cytology; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007074:Immunoglobulin G / Q000737:chemistry; D007700:Kinetics; D051379:Mice; D008819:Mice, Nude; D008969:Molecular Sequence Data; D018482:Muscle, Skeletal / Q000378:metabolism; D009368:Neoplasm Transplantation; D009389:Neovascularization, Pathologic; D019151:Peptide Library; D011485:Protein Binding; D013045:Species Specificity; D014471:Umbilical Veins / Q000166:cytology; D042461:Vascular Endothelial Growth Factor A / Q000737:chemistry / Q000276:immunology / Q000378:metabolism*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D019151:Peptide Library; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab